文献速递前列腺增生与排尿功能障碍泌尿系感染

维贝格龙在合并良性前列腺增生的男性膀胱过度活动症患者中的临床有意义改善:3期COURAGE试验的应答者分析

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.
PubMed 文献 · Urology · 2025-09-01

该事后应答者分析基于3期COURAGE试验,纳入1105例接受BPH药物治疗且伴OAB的≥45岁男性,随机接受维贝格龙75 mg或安慰剂24周。第12周时,维贝格龙组达到排尿次数、夜尿次数和急迫性尿失禁应答标准的比例均显著高于安慰剂组,IPSS和OAB-q改善也更明显,疗效一般维持至第24周。

要点

  • 维贝格龙75 mg可提高OAB合并BPH男性达到临床有意义应答的比例。
  • 第12周排尿次数应答率33.3% vs 20.5%,夜尿34.6% vs 26.8%,急迫性尿失禁65.8% vs 53.0%。
  • IPSS和OAB-q评分改善在维贝格龙组更显著,疗效一般维持至24周。

核心结论

  • 在3期COURAGE试验的事后应答者分析中,维贝格龙组相比安慰剂组在烦人的OAB症状上达到临床相关减轻,并改善IPSS和OAB-q评分。

研究设计与样本

  • 3期COURAGE试验(NCT03902080)的事后应答者分析,男性≥45岁、接受BPH药物治疗且伴OAB,随机1:1接受维贝格龙75 mg或安慰剂24周。
  • 共1105例参与者,1080例纳入分析(维贝格龙n=538,安慰剂n=542)。

主要发现

  • 第12周,维贝格龙组达到排尿次数应答(≤8次/日)的比例为33.3%,安慰剂组为20.5%(P<.0001)。
  • 第12周,维贝格龙组达到夜尿应答(≤1次/夜)的比例为34.6%,安慰剂组为26.8%(P=.0036)。
  • 第12周,维贝格龙组达到急迫性尿失禁应答(≤1次/日)的比例为65.8%,安慰剂组为53.0%(P=.0267)。
  • 第12周,维贝格龙组相比安慰剂组更多参与者达到IPSS存储、排尿和总分≥3分下降以及OAB-q子量表评分≥10分改善。
  • 结果一般维持至第24周。

关键数值与推荐

  • 应答标准包括:每日排尿≤8次、每晚夜尿≤1次、每日急迫性尿失禁≤1次、IPSS评分下降≥3分、OAB-q子量表评分改善≥10分。
  • 应答终点采用Cochran-Mantel-Haenszel共同风险差估计进行分析。

临床怎么用

  • 对于接受BPH药物治疗但仍有OAB症状的男性,维贝格龙75 mg可考虑作为改善排尿频率、夜尿和急迫性尿失禁的联合治疗选择。

局限性

  • 本分析为事后分析,应答标准为研究设定的阈值,需结合临床实践个体化解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To demonstrate the impact of vibegron treatment in the phase 3 COURAGE trial (NCT03902080) on clinically meaningful response parameters in men with overactive bladder (OAB) receiving pharmacological therapy for benign prostatic hyperplasia (BPH) as measured by standard, validated patient-reported outcomes. METHODS: Men age ≥45 years with OAB receiving pharmacotherapy for BPH were randomly assigned 1:1 to vibegron 75 mg or placebo for 24 weeks. Participants completed bladder diaries assessing changes in micturition frequency, nocturia, and urge urinary incontinence (UUI); International Prostate Symptom Score (IPSS); and OAB questionnaire (OAB-q). Post hoc analyses assessed the percentage of responders (ie, ≤8 daily micturitions, ≤1 nightly nocturia episodes, ≤1 daily UUI episodes, ≥3-point decrease in IPSS scores, ≥10-point improvement in OAB-q subscale scores). Responder endpoints were analyzed using a Cochran-Mantel-Haenszel common risk difference estimation. RESULTS: Of 1105 participants, 1080 were included in the analysis (vibegron, n=538; placebo, n=542). At week 12, greater percentages of participants receiving vibegron vs placebo achieved responder endpoints for micturitions (33.3% vs 20.5%, respectively; P<.0001), nocturia episodes (34.6% vs 26.8%; P=.0036), and UUI episodes (65.8% vs 53.0%; P=.0267). At week 12, greater percentages of participants receiving vibegron versus placebo achieved a ≥3-point decrease in IPSS storage, voiding, and total scores and 10-point increase in OAB-q subscale scores. Results were generally sustained through week 24. CONCLUSION: In this post hoc responder analysis from the phase 3 COURAGE trial, participants receiving vibegron vs placebo achieved clinically relevant reductions in bothersome OAB symptoms, as well as improvements in IPSS and OAB-q scores.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Peters KM, Owens-Grillo J, Thomas E, et al. Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial. Urology. 2025. PMID: 40902908. doi:10.1016/j.urology.2025.08.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。